| Overview |
| bs-5502R-Cy5 |
| MEF2D(Ser444) Polyclonal Antibody, Cy5 Conjugated |
| WB, FCM, IF(IHC-P), IF(IHC-F), IF(ICC) |
| Human, Mouse, Rat |
| Cow, Pig, Horse, Rabbit |
| Specifications |
| Cy5 |
| Rabbit |
| KLH conjugated synthetic phosphopeptide derived from human MEF2D around the phosphorylation site of Ser444 |
| Ser444 |
| Polyclonal |
| IgG |
| 1ug/ul |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 4209 |
| Nucleus |
| MEF2Dphospho S444; DKFZp686I1536; MADS box transcription factor 2 polypeptide D; Mef2d; MEF2D_HUMAN; myocyte enhancer factor 2D; Myocyte specic enhancer factor 2, polypeptide D; Myocyte specic enhancer factor 2D; myocyte-specic enhancer factor 2D. |
| MEF2D is a member of the myocyte-specific enhancer factor 2 (MEF2) family of transcription factors. Members of this family are involved in control of muscle and neuronal cell differentiation and development, and are regulated by class II histone deacetylases. Fusions of the encoded protein with Deleted in Azoospermia-Associated Protein 1 (DAZAP1) due to a translocation have been found in an acute lymphoblastic leukemia cell line, suggesting a role in leukemogenesis. The encoded protein may also be involved in Parkinson disease and myotonic dystrophy. Alternative splicing results in multiple transcript variants. |
| Application Dilution |
| WB |
1:300-5000 |
| FCM |
1:20-100 |
| IF(IHC-P) |
1:50-200 |
| IF(IHC-F) |
1:50-200 |
| IF(ICC) |
1:50-200 |
Powered by Bioz